Literature DB >> 20206665

Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys.

Teresa Zariñán1, Marco A Perez-Solís, Guadalupe Maya-Núñez, Patricia Casas-González, P Michael Conn, James A Dias, Alfredo Ulloa-Aguirre.   

Abstract

Current evidence indicates that G protein-coupled receptors form dimers that may affect biogenesis and membrane targeting of the complexed receptors. We here analyzed whether expression-deficient follicle-stimulating hormone receptor (FSHR) mutants exert dominant negative actions on wild-type FSHR cell surface membrane expression. Co-transfection of constant amounts of wild-type receptor cDNA and increasing quantities of mutant (R556A or R618A) FSHR cDNAs progressively decreased agonist-stimulated cAMP accumulation, [(125)I]-FSH binding, and plasma membrane expression of the mature wild-type FSHR species. Co-transfection of wild-type FSHR fragments involving transmembrane domains 5-6, or transmembrane domain 7 and/or the carboxyl-terminus specifically rescued wild-type FSHR expression from the transdominant inhibition by the mutants. Mutant FSHRs also inhibited function of the luteinizing hormone receptor but not that of the thyrotropin receptor or non-related receptors. Defective intracellular transport and/or interference with proper maturation due to formation of misfolded mutant:wild-type receptor complexes may explain the negative effects provoked by the altered FSHRs. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206665      PMCID: PMC2854281          DOI: 10.1016/j.mce.2010.02.027

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  77 in total

1.  The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities.

Authors:  Shirley Wilson; Graeme Wilkinson; Graeme Milligan
Journal:  J Biol Chem       Date:  2005-06-09       Impact factor: 5.157

Review 2.  A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization.

Authors:  G Milligan
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 3.  Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions.

Authors:  László Szidonya; Miklós Cserzo; László Hunyady
Journal:  J Endocrinol       Date:  2008-03       Impact factor: 4.286

4.  Crystal structure of the ligand-free G-protein-coupled receptor opsin.

Authors:  Jung Hee Park; Patrick Scheerer; Klaus Peter Hofmann; Hui-Woog Choe; Oliver Peter Ernst
Journal:  Nature       Date:  2008-06-18       Impact factor: 49.962

5.  In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles.

Authors:  Alfredo Leaños-Miranda; Alfredo Ulloa-Aguirre; Jo Ann Janovick; P Michael Conn
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

6.  Inhibition of human type i gonadotropin-releasing hormone receptor (GnRHR) function by expression of a human type II GnRHR gene fragment.

Authors:  Adam J Pawson; Stuart Maudsley; Kevin Morgan; Lindsay Davidson; Zvi Naor; Robert P Millar
Journal:  Endocrinology       Date:  2005-03-10       Impact factor: 4.736

Review 7.  G protein-coupled receptor dimers: functional consequences, disease states and drug targets.

Authors:  Matthew B Dalrymple; Kevin D G Pfleger; Karin A Eidne
Journal:  Pharmacol Ther       Date:  2008-04-08       Impact factor: 12.310

8.  Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles.

Authors:  Kimberley A Beaumont; Sri N Shekar; Sri L Shekar; Richard A Newton; Michael R James; Jennifer L Stow; David L Duffy; Richard A Sturm
Journal:  Hum Mol Genet       Date:  2007-07-05       Impact factor: 6.150

9.  Functional and structural roles of conserved cysteine residues in the carboxyl-terminal domain of the follicle-stimulating hormone receptor in human embryonic kidney 293 cells.

Authors:  Aída Uribe; Teresa Zariñán; Marco A Pérez-Solis; Rubén Gutiérrez-Sagal; Eduardo Jardón-Valadez; Angel Piñeiro; James A Dias; Alfredo Ulloa-Aguirre
Journal:  Biol Reprod       Date:  2008-01-16       Impact factor: 4.285

Review 10.  Multiple facets of follicle-stimulating hormone receptor function.

Authors:  Alfredo Ulloa-Aguirre; Teresa Zariñán; Ana Ma Pasapera; Patricia Casas-González; James A Dias
Journal:  Endocrine       Date:  2008-02-02       Impact factor: 3.633

View more
  15 in total

Review 1.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

Review 2.  Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.

Authors:  Alfredo Ulloa-Aguirre; Teresa Zariñán; James A Dias; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2013-06-24       Impact factor: 4.102

3.  Follicle-stimulating hormone receptor (FSHR) alternative skipping of exon 2 or 3 affects ovarian response to FSH.

Authors:  Cengiz Karakaya; Ozlem Guzeloglu-Kayisli; Rebecca J Hobbs; Tsilya Gerasimova; Asli Uyar; Mehmet Erdem; Mesut Oktem; Ahmet Erdem; Seyhan Gumuslu; Deniz Ercan; Denny Sakkas; Pierre Comizzoli; Emre Seli; Maria D Lalioti
Journal:  Mol Hum Reprod       Date:  2014-03-25       Impact factor: 4.025

Review 4.  Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors.

Authors:  P Michael Conn; Alfredo Ulloa-Aguirre
Journal:  Adv Pharmacol       Date:  2011

5.  Emerging roles for the FSH receptor adapter protein APPL1 and overlap of a putative 14-3-3τ interaction domain with a canonical G-protein interaction site.

Authors:  James A Dias; Smita D Mahale; Cheryl A Nechamen; Olga Davydenko; Richard M Thomas; Alfredo Ulloa-Aguirre
Journal:  Mol Cell Endocrinol       Date:  2010-06-19       Impact factor: 4.102

6.  Single-molecule analyses of fully functional fluorescent protein-tagged follitropin receptor reveal homodimerization and specific heterodimerization with lutropin receptor.

Authors:  Joseph E Mazurkiewicz; Katharine Herrick-Davis; Margarida Barroso; Alfredo Ulloa-Aguirre; Barbara Lindau-Shepard; Richard M Thomas; James A Dias
Journal:  Biol Reprod       Date:  2015-03-11       Impact factor: 4.285

7.  Trafficking of the follitropin receptor.

Authors:  Alfredo Ulloa-Aguirre; James A Dias; George Bousfield; Ilpo Huhtaniemi; Eric Reiter
Journal:  Methods Enzymol       Date:  2013       Impact factor: 1.600

Review 8.  Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.

Authors:  P Michael Conn; David C Smithson; Peter S Hodder; M David Stewart; Richard R Behringer; Emery Smith; Alfredo Ulloa-Aguirre; Jo Ann Janovick
Journal:  Pharmacol Res       Date:  2013-12-25       Impact factor: 7.658

Review 9.  Role of the Extracellular and Intracellular Loops of Follicle-Stimulating Hormone Receptor in Its Function.

Authors:  Antara A Banerjee; Smita D Mahale
Journal:  Front Endocrinol (Lausanne)       Date:  2015-07-17       Impact factor: 5.555

10.  Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.

Authors:  Jo Ann Janovick; Timothy P Spicer; Thomas D Bannister; Louis Scampavia; P Michael Conn
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.